APUS APUS
Company Profile ↓Company Overview
APUS (APUS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -70.57% |
| 6 Months: | -72.81% |
| 3 Months: | -84.50% |
| 1 Month: | -37.42% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 88.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -271.73K | -427.76K | -300.00K | -364.37K | -2.66M | -1.84M | -12.19M |
| Net Income | -296.47K | -449.36K | -332.52K | -402.40K | -2.66M | -1.78M | -35.06M |
| Diluted EPS | -0.04 | -0.06 | -0.04 | -0.05 | -0.26 | -0.14 | -2.26 |
| R&D Expense | - | - | - | - | 651.78K | 619.69K | 901.14K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -747.44K | -1.28M | -11.91M |
| Net Income | -777.69K | -1.39M | -6.00M |
| Diluted EPS | -0.17 | -0.18 | -0.55 |
| R&D Expense | 98.54K | - | 1.63M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 422.08K | 13.06K | 164.18M |
| Total Equity | -713.61K | 31.87K | -1.36M | 153.35M |
| Cash & Equivalents | - | 410.48K | 3.46K | 1.64M |
| Total Liabilities | - | 390.21K | 1.37M | 10.84M |
| Current Liabilities | - | 123.32K | 1.02M | 10.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -627.79K | -733.53K | -8.93M |
| Investing Cash Flow | - | - | -10.06M |
| Financing Cash Flow | 1.03M | 326.50K | 20.62M |
| Capital Expenditure | - | - | -57.33K |
| Free Cash Flow | - | - | -8.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -2,440.3% | 102.3% | -3.9% |
| ROCE % | -250.2% | 126.1% | -7.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APUS
Eligible U.S. Users Can Access NILA Ahead of Expected October Launch - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSUZHWHlpYjAzUXR6RlczYnluN3d5aTNHRURLVnRlRzhuaFd3YVV1bmgxdkVEVndLQmQ4MGdMVXJ5ZjRtTENzLTFDdTkzakRfZDU4eXlGeDJ0SVZfRTVfaUNzN0wyNW0tOUhRblJfRFEySDhuSThqdjhRem9INHFLd2k1aFFqS1FVR3F1NW…
APUS|Apimeds Pharmaceuticals US Inc|Price:4.860|Chg%:-0.290 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFBocXVuZXBQNkwybG1YLUZyd0RNeERBTnRiZXNwbHU0Zldfcm5UeVZPLWIxbkU1anlWS3J3emVmR2lST1FLZXRhbHg1Tkd4WEVoaE1IdHBSWjg4QQ?oc=5" target="_blank">APUS|Apimeds Pharmaceuticals US Inc|Price:4.8…
Apimeds Pharmaceuticals US to implement 1-for-10 reverse stock split, trading adjusted March 26 - TradingView
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOYmhWSlhHTS0zaTJHa3MtZWotdmFqNVB5UWhWdVlidXF1bVNiU1ZvWXVNZi1KV1lZenFBVF84bFM3eDctLXpja01pUUVjN3U0X2drbzVORHRqbG5RVFJDczJvV1B1Zm5RYkVvc3J1cXc1el95LWozZmE1LUdwMFNHamtMTWludG5rT2ZveG…
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOb2NhNUV2WjcwYjJHazRfQUc5cVFYNnUxLTlya05Oc0ZvVUtTRWt1bEl2R2hYeDRaaVlvYlAwQ3UzcmROdnRzSmpnZDlGWDVOa0hEZUt3VS1yZ1RtdnlGT2t1cXZ2d3FkU1hocFYyUXdzR2hEZlhTQnZsaHByTUlBbzhYbUFLZWlYREJfc1…
Apimeds settles disputes, stock to resume trading today - Investing.com
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOZEdVYTNJSlgydHhwaV95S3JvZHQtVnQ4QnJmRFlEaGJpOFZCdFMwQzNvMEdadVlaYzJRd3FJN0NHRWlpdkVHN01jX3A1TkxiQ1lBWFdBOVdJY0E2NVFDUG5NeXZmWmRmTW0tcDlDcDZtYTRrYlhFT0tVaXhFYV9XQ0ttSGM5cGRIcmFtbU…
NILA Set for First U.S.-Licensed Exchange Availability Aug. 3 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMXRlSnR1VHR6UUxkQ2FwWFNCVkFyd3hNUnlPTHhNN0t6X1lEM0ppNVgxVzg0QzhOMlg0YlVtOHFKRnVwNVFFUWxmd0ZWX3d1Z2pqN1RGTDcwdVJpN2huWl91NXZ1aDhodUVWcWJJNDFYZHo5X1ZHdmw4SzRuOUgycnBrVklTeThpczhTbn…
APUS — Frequently Asked Questions
What is the current share price of APUS?
As of 2026-08-05 17:25 PDT, APUS trades at $4.65 on NASDAQ/NYSE. Its 52-week range is $4.65 to $38.95.
What is the P/E ratio of APUS?
APUS trades at a trailing price-to-earnings (P/E) ratio of -8.45.
What is the return on equity (ROE) of APUS?
APUS has a return on equity (ROE) of -3.91%. Its return on capital employed (ROCE) is -7.76%.
Is APUS a good stock to buy?
This page provides a data-driven analysis of APUS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.